文献速递胸部肿瘤

免疫治疗转移性非小细胞肺癌试验中缓解率与无进展生存期和总生存期的相关性:FDA汇总分析

Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis.
PubMed 文献 · Lancet Oncol · 2024-03-05

该FDA汇总分析纳入2016年6月24日至2021年3月16日提交的13项一线随机试验共9285例转移性非小细胞肺癌患者,评估免疫检查点抑制剂试验中总缓解率及无进展生存期与总生存期的相关性。试验水平R²分别为0.61和0.70,患者水平缓解者总生存期优于非缓解者(HR 0.28)。

要点

  • 试验水平总缓解率与总生存期相关性R²=0.61,无进展生存期与总生存期相关性R²=0.70。
  • 患者水平缓解者较非缓解者总生存期更长,HR 0.28(95%CI 0.26-0.30)。
  • 缓解者中试验组总生存期优于对照组,HR 0.54(95%CI 0.48-0.61)。

核心结论

  • 在该汇总分析中,总缓解率及无进展生存期与总生存期的相关性总体为中等。
  • 研究结果支持在可行时对转移性非小细胞肺癌一线免疫检查点抑制剂随机试验的成熟总生存期数据进行常规分析。

研究设计与样本

  • 美国食品药品监督管理局汇总分析,纳入2016年6月24日至2021年3月16日提交的一线随机试验。
  • 纳入年龄≥18岁、东部肿瘤协作组体能状态0-1分的转移性鳞状及非鳞状非小细胞肺癌患者。
  • 合格试验为试验组评估至少一种免疫检查点抑制剂对比对照组化疗。
  • 共纳入13项试验、9285例患者,评估免疫检查点抑制剂单药或联合化疗对比单纯化疗。

主要发现

  • 试验水平总缓解率与总生存期相关性的R²为0.61(95%CI 0.32-0.84)。
  • 试验水平无进展生存期与总生存期相关性的R²为0.70(95%CI 0.40-0.89)。
  • 按PD-L1表达评估亚组时相关性范围为弱至中等,在免疫检查点抑制剂单药或联合化疗试验中结果一致。
  • 患者水平缓解者较非缓解者总生存期更长,HR 0.28(95%CI 0.26-0.30)。
  • 缓解者中试验组较对照组总生存期更长,HR 0.54(95%CI 0.48-0.61)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiographic changes might not fully capture the treatment effects of immune checkpoint inhibitors (ICIs). We aimed to assess correlations of overall response rate and progression-free survival with overall survival in trials of ICIs for metastatic non-small-cell lung cancer (NSCLC). METHODS: To assess trial-level and patient-level correlations of overall response rate and progression-free survival with overall survival, we conducted a pooled analysis of first-line randomised trials (including patients aged ≥18 years with metastatic squamous and non-squamous NSCLC and an Eastern Cooperative Oncology Group performance status of 0-1) submitted to the US Food and Drug Administration from June 24, 2016, to March 16, 2021. Eligible trials evaluated at least one ICI in the experimental group versus chemotherapy in the control group. At the trial level, we used weighted linear regression to derive coefficients of determination (R2). At the patient level, we used Cox proportional hazards models to compare overall survival between responders versus non-responders per Response Evaluation Criteria in Solid Tumours (version 1.1). FINDINGS: A total of 13 trials including 9285 patients evaluated ICIs alone or in combination with chemotherapy versus chemotherapy alone. At the trial level, the R2 was 0·61 (95% CI 0·32-0·84) for correlation of overall response rate with overall survival and 0·70 (0·40-0·89) for correlation of progression-free survival with overall survival. Correlations ranged from weak to moderate when evaluating subgroups by PD-L1 expression and were consistent across trials evaluating ICIs alone or in combination with chemotherapy. At the patient level, responders had longer overall survival than non-responders (hazard ratio [HR] 0·28 [95% CI 0·26-0·30]). Among responders, overall survival was longer in patients enrolled in experimental groups than in control groups (HR 0·54 [95% CI 0·48-0·61]). INTERPRETATION: Correlations of overall response rate and progression-free survival with overall survival were generally moderate in this pooled analysis. The findings support routine analysis of mature overall survival data, where feasible, in first-line randomised trials of ICIs for metastatic NSCLC. FUNDING: US Food and Drug Administration.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Goulart BHL, Mushti SL, Chatterjee S, et al. Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis. Lancet Oncol. 2024. PMID: 38458207. doi:10.1016/S1470-2045(24)00040-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。